Life Sciences Venture Capital Monitor - FCF Fox Corporate Finance | FCF Life Sciences - FCF Fox ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
FCF Fox Corporate Finance | FCF Life Sciences Life Sciences Venture Capital Monitor August 2020 Antibody Part of FCF Life Sciences Research Series Strategic Financing Advisory in Life Sciences
Agenda FCF LIFE SCIENCES O V E RV I E W
Overview
Overview Service Portfolio Facts and Figures
Focus on Biotechnology, MedTech and HealthTech Over Over
Life Sciences Life Sciences
Management Team of 100 years EUR 2bn
FCF advises innovative companies on arranging, structuring and placing Advisory in aggregated Life Sciences
Presentation 8
equity and debt transactions in a holistic financing strategy approach. Board Life Sciences transaction
Integrated based in Munich
Together with its industry advisors, FCF Life Sciences provides valuable experience volume1
Financial
support on the strategic positioning of its clients Modeling
Post- Over 4
Access to
Strategic Financing Advisory Transaction 80 Leading regularly
Support > 1000
completed Life EIB advisor published Life
international
FCF advises with its dedicated Life Sciences team on the following Investor Sciences in Europe Sciences
investors
transaction types: Screening transactions1 reports
1 including Professionals and Life Sciences Advisors
Investor / IB
Venture Capital Venture Debt Roadshow
+ +
Life Sciences Research Series
Growth Equity Due
Diligence
Support Venture Capital Monitor Public Equity Monitor
Equity & Debt is a monthly is the most detailed
Life Sciences Team Fundraising
published overview analysis of
Financing of venture capital European publicly
Strategy listed companies,
transactions of Life
Advisory
Sciences companies from the Life
Closing Sciences sectors
Arno Fuchs Dr. Mathias Sebastian Alexander Kuhn Assistance
CEO Schott Sommer Analyst
Director Associate
Term Sheet
Negotiation Venture Capital Report IPO Report
analyses the latest examines recent
IPO
Execution Venture Capital IPO trends in the
Support funding activities in Life Sciences sector,
Life
Dr. Alexandra Goll Claus Schalper Prof. Dr. Enno Spillner the Life Sciences with a strong focus
Science
Former Co-Founder & former Horst Domdey CFO Evotec
General Partner CFO Pieris Pharma Co-Founder of Medigene Advisory sector in Europe on the comparison
TVM Capital & board member BioM Board (extract from
service portfolio) and the US of European and US
characteristics
3Executive Summary
The FCF Life
FCF Life Sciences Venture Capital Monitor Recipients
Sciences Venture
Capital Monitor is a is a monthly published overview of biotechnology, pharmaceutical, The FCF Life Sciences Venture Capital Monitor targets the following
monthly published medical technology and healthcare technology companies, recipients:
overview focusing on displaying venture capital financing trends in the European life ▪ Corporates / Executives ▪ Venture capital investors
the venture capital science industry ▪ Institutional investors ▪ Family Offices / High-
financing ▪ Private equity investors net-worth individuals
environment in the ▪ Advisors
biotechnology, Scope
pharmaceutical,
medical technology The selection of companies is based on the following criteria: Availability
and healthcare
technology ▪ Focus on transactions with European headquartered life science The FCF Life Sciences Venture Capital Monitor is available on FCF’s
segments, and can companies and available deal volume website at “https://www.fcf.de/de/research/life-science-research“
be used as a quick ▪ Companies operating in the biotechnology, pharmaceutical,
reference for medical technology, healthcare technology, services or other life Data
investors, corporates science related sectors
and professionals All input data is provided by Pitchbook or GlobalData and is not
▪ The therapeutics sector is further divided into the following independently verified by FCF. Ratio and multiple calculations are
indications: Oncology, Cardiovascular, Central Nervous System, driven based on the input data available. For additional information
Gastrointestinal, Hematological, Infectious Diseases, and disclaimer, please refer to the last page
More advanced, Immunology, Metabolic, Ophthalmology, Rare Diseases,
detailed and / or Respiratory, Diversified and Others
customized reports
are available upon
request To recommend colleagues or fellow investors to be added to the If you have questions, comments or ideas, please do not hesitate
mailing list, kindly send an email with the respective contact to contact us
information
4Agenda V E N T U R E C AP I TAL T R AN S AC T I O N S AUGUST 2020
European Venture Capital Transactions in Life Sciences
August 2020
Deal Total
Volume Raised
Overview (YTD) # Date Company HQ Subsector Vertical - Indication / Stage Company Description Series (EURm) (EURm) Deal Synopsis
Cumulative Financing Volume (EURm) Developer of monolithic
7,000 6,104 detectors and x-ray technology
Monolithic Detectors /
1 31-08-20 G-ray CHE MedTech intended to make medical A 26 26 The company raised CHF 28 million of Series A venture on August 31, 2020.
6,000 On market
imaging solutions more precise
5,000 and secure.
4,000
3,000
2,000 Operator of a biotech company
2020 The company raised EUR 4.5 million of Series A venture funding on August 31, 2020.
1,000 Biodol Biotech / Central Nervous System / intended to develop an
2019 2 31-08-20 FRA A 5 5 The funds will be used to develop FLT3 inhibitors for the treatment of chronic and
0 Therapeutics Pharma Pre-clinic innovative treatment for chronic
neuropathic pain.
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec pain.
Financing Volume (August 2020): EUR 300m
Subsectors Indications1
Healthcare The company raised EUR 4.3 million of Series A venture funding on August 31, 2020,
AI-based Real-World Developer of an AI-based real-
Services putting the company's pre-money valuation at an estimated EUR 6.38 million. The
3 31-08-20 Semalytix DEU HealthTech Evidence Generation Tool / world evidence generation tool A 4 4
funds will be used to expand its business development with pharma companies and
On market designed to ingest data.
HealthTech Immunology the wider healthcare market.
3%
Others
20% 29% 29%
EUR EUR
6,104m 55% Biotech / 3,348m Manufacturer of on-demand
Pharma 4% Customized Prosthetic customized prosthetic products The company raised EUR 430,000 of venture funding on August 31, 2020. The funds
22% Gastro- 5% 4 31-08-20 Anatomic Studios SWE MedTech Products / intended to empower and inspire -European Venture Capital Transactions in Life Sciences
August 2020
Deal Total
Volume Raised
Overview (YTD) # Date Company HQ Subsector Vertical - Indication / Stage Company Description Series (EURm) (EURm) Deal Synopsis
Cumulative Financing Volume (EURm) The company raised GBP 9.73 million of Series A venture funding on August 20, 2020,
Developer of a novel molecular
7,000 6,104 putting the company's pre-money valuation at GBP 16.06 million. The funding will be
Biotech / Diagnostics / assay intended to broaden
6,000 9 20-08-20 Biofidelity GBR A 11 12 used to accelerate the development and clinical validation of oncology panels for
Pharma Developing access to the highest precision
treatment selection and patient monitoring in oncology, and to bring these assays
5,000 testing to all patients.
rapidly to market through direct sale, partnering and collaboration.
4,000
3,000
2,000 Provider of a medical research
2020 Medical Research Data The company raised $12 million of Series A venture on August 19, 2020. The funding
1,000 data platform intended to
2019 10 19-08-20 Castor NLD HealthTech Platform / A 10 16 will be used by the company to build out its patient-facing technology, which includes
0 facilitate electronic data capture
On market video-enabled consent to remotely enroll patients in clinical trials.
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec for medical research.
Financing Volume (August 2020): EUR 300m
Subsectors Indications1
Healthcare Developer of novel technology The company raised GBP 250,000 of venture funding on August 19, 2020. The funding
Services Magnitude Healthcare Diagnostics /
11 19-08-20 GBR intended to discover and develop -European Venture Capital Transactions in Life Sciences
August 2020
Deal Total
Volume Raised
Overview (YTD) # Date Company HQ Subsector Vertical - Indication / Stage Company Description Series (EURm) (EURm) Deal Synopsis
Cumulative Financing Volume (EURm)
Developer of a healthcare The company raised EUR 8.2 million of venture funding on August 11, 2020. In
7,000 6,104 Online Doctor Consultation
Healthcare platform intended to serve support of the transaction, the firm received debt financing in the form of a loan. The
6,000 17 11-08-20 Practio GBR Platform / - 8 8
Services patients with the help of local funds will be used to accelerate the deployment in the UK and to enter the German
On market
5,000 pharmacies. market later this year with other countries to follow from 2021 onwards.
4,000
3,000
2,000
2020 Implant for Heart Valve Developer of an implant The company raised EUR 20 million of Series B venture funding on August 7, 2020.
1,000
2019 18 07-08-20 InnovHeart ITA MedTech Dysfunction / technology intended to minimally B 20 20 The funds will be used to complete the first in human clinical evaluation of the
0 On market replace the invasive mitral valve. company's unique system using a trans-apical approach.
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Financing Volume (August 2020): EUR 300m
Subsectors Indications1
Healthcare Owner and operator of a The company raised $13 million of Series A venture on August 7, 2020. The proceeds
Services Biotech / Infectious Diseases / biotechnology company intended will support the development of the HTI immunogen as a therapeutic vaccine against
19 07-08-20 Aelix Therapeutics ESP A 11 11
Pharma Phase II to develop a therapeutic vaccine HIV infection up to the completion of a Phase 2 proof-of-concept efficacy trial in HIV-
HealthTech Immunology to help people with HIV. infected individuals.
3%
Others
20% 29% 29%
EUR EUR
6,104m 55% Biotech / 3,348m
Pharma 4% Developer of an e-healthcare
22% The company raised EUR 6.1 million of Series A venture funding on August 6, 2020.
Gastro- 5% E-Healthcare Application / application intended to provide
MedTech intestinal 21% 20 06-08-20 Elma ESP HealthTech A 6 7 The funding raised will be used to boost product development, the business growth
12% On market quicker doctor-patient
Infectious and expansion of the team to put to the service user.
Oncology communication in Spain.
Diseases
Central
Nervous
System
The company raised EUR 66 million of Series A venture funding on August 6, 2020,
Top Company Origins Top Investor Origins Biotech / Oncology /
Developer of T cell receptors putting the company's pre-money valuation at an estimated EUR 2.53 billion. The
21 06-08-20 T-Knife DEU intended for T cell therapy of A 66 132 funds will be used by the company to advance at least four programs into the clinic,
Pharma Pre-clinic
cancer. ramping-up preclinical work for additional selected proprietary pipeline candidates and
Others discovering TCRs against novel targets.
Others
24% 27% 31% 29%
EUR EUR
9%
6,104m 6,104m
Developer of a genome-analysis The company raised EUR 2.4 million of Pre-Series A venture funding on August 6,
15% 11% Genome-Analysis Platform /
12%
9% 22 06-08-20 Made of Genes ESP HealthTech platform designed to understand A 2 3 2020. The funds will be used to launch and promote its VITAL and HEALTH lines, as
On market
13% 10% 10% human genomes. well as the a new product.
Top 5 Deals Top 5 Investors
Deal # of Deal Developer of a portable
# Company HQ Volume Series # Investor HQ Deals Volume2
Portable Wheelchair
wheelchair technology intended
23 06-08-20 Mooevo ESP MedTech Technology / -European Venture Capital Transactions in Life Sciences
August 2020
Deal Total
Volume Raised
Overview (YTD) # Date Company HQ Subsector Vertical - Indication / Stage Company Description Series (EURm) (EURm) Deal Synopsis
Cumulative Financing Volume (EURm)
7,000 6,104 Developer of a health tech
Audio Gadget / The company raised GBP 1.32 million of venture funding on August 5, 2020, putting
6,000 25 05-08-20 Kokoon GBR MedTech gadget designed to offer sleep - 1 6
On market the company's pre-money valuation at GBP 9.17 million.
and relaxation using audio.
5,000
4,000
3,000
2,000 Developer of real-time and
2020 accurate intra-uterine monitoring The company raised GBP 3.9 million of Series A venture on August 3, 2020. The funds
1,000 Monitoring Device /
2019 26 03-08-20 VivoPlex GBR MedTech device built for optimization of A 4 6 will be used for a clinical feasibility study and to gain a European CE mark for its first
0 Developing
fertility treatment and uterine product, which will enable them to sell their product in the market.
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec health.
Financing Volume (August 2020): EUR 300m
Subsectors Indications1
Healthcare
Services
HealthTech Immunology
3%
Others
20% 29% 29%
EUR EUR
6,104m 55% Biotech / 3,348m
Pharma 4%
22% Gastro- 5%
MedTech intestinal 21%
12%
Infectious
Oncology
Diseases
Central
Nervous
System
Top Company Origins Top Investor Origins
Others
Others
24% 27% 31% 29%
EUR EUR
9%
6,104m 6,104m
15% 9% 11%
12%
13% 10% 10%
Top 5 Deals Top 5 Investors
Deal # of Deal
# Company HQ Volume Series # Investor HQ Deals Volume2
1 2Eyes Vision 600 B 1 Bpifrance 24 71
CureVac
2 560 G 2 Venture Kick 20 2
(NAS: CVAC)
3 LumiraDx 278 C Mercia Asset
3 11 7
Management
Arvelle
4 205 A High-Tech
Therapeutics 4 10 13
Gründerfonds
Oxford
5 Nanopore 186 - 5 Novo Holdings 9 66
Technologies
Source: PitchBook as of 15.09.2020; FCF Equity Research; GlobalData
Note: All volumes in EURm; financing rounds without deal values are excluded 9
1Only includes biotechnology and pharmaceutical deals; 2 Proportional attribution of deal values to investors participating in a transaction (transaction volume / # investors by financing round)Contact Details & Disclaimer
DISCLAIMER
This document does not constitute an offer or invitation to purchase or
subscribe for any securities, and neither this document nor anything contained
herein shall form the basis of or may be relied upon in connection with any
contract or commitment whatsoever. No representation or warranty (express or
FCF Fox Corporate Finance GmbH implied) is made as to, and no reliance should be placed on, any information,
including projections, estimates, targets and opinions, contained herein, and no
Maximilianstrasse 12-14 ▪ 80539 Munich ▪ Germany liability whatsoever is accepted as to any errors, omissions or misstatements
Telephone +49 (89) 206 0409-0 ▪ Facsimile +49 (89) 206 0409-299 contained herein, and, accordingly, neither FCF nor any of its officers, directors
info@fcf.de ▪ www.fcf.de or employees accepts any liability whatsoever arising directly or indirectly from
the use of this document. By accepting this document you acknowledge that
you will be solely responsible for your own assessment of the market and the
market position of the Company and that you will conduct your own analysis
and be solely responsible for forming your own view of the potential future
Arno Fuchs Dr. Mathias Schott performance of the Company's business. This document contains certain
Chief Executive Officer Director
forward-looking statements, including assumptions, opinions and views cited
P: +49 (89) 206 0409-100 P: +49 (89) 206 0409-123 from third party sources. Various known and unknown risks, uncertainties and
M: +49 (172) 863 6777 M: +49 (174) 301 1846
other factors could cause the actual results, financial position, development or
arno.fuchs@fcf.de mathias.schott@fcf.de
performance of the Company to differ materially from the estimations
expressed or implied herein. FCF does not guarantee that the figures,
assumptions and calculations underlying such historical and forward looking
Sebastian Sommer Alexander Kuhn statements are free from errors nor does FCF accept any responsibility for the
Associate Analyst
future accuracy of the opinions expressed in this document or the actual
P: +49 (89) 206 0409-130 P: +49 (89) 206 0409-120 occurrence of the forecasted developments.
M: +49 (172) 839 5738 M: +49 (173) 590 6671
sebastian.sommer@fcf.de alexander.kuhn@fcf.de © FCF Fox Corporate Finance GmbH 2020
10You can also read
